Indexado en

Licencia y uso

Citaciones

Altmetrics

Grant support

Funding was received from Sociedad Espanola de Nefrologia (SEN), Sociedad Madrilena de Nefrologia (SOMANE), Fundacion Renal Inigo Alvarez de Toledo (FRIAT), Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA_COR-CM; Instituto de Salud Carlos III (ISCIII) Fondo de investigacion Sanitaria/Fondo Europeo de Desarrollo regional ( FEDER) (PI20/00744, PI22/00469, PI22/00050, PI21/00251, PI23/00627), ERA-PerMed- JTC2022 (SPAREKID AC22/00027), SIGNAL (AC22/00028), RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union- NextGenerationEU, Mecanismo para la Recuperacion y la Resiliencia (MRR) and SPACKDc PMP21/00109, FEDER funds, COST Action PERMEDIK CA21165, supported by COST ( European Cooperation in Science and Technology) ; PREVENTCKD Consortium Project ID: 101101220 Programme: EU4H DG/Agency: HADEA. KitNewCare, Project ID: 101137054, Call: HORIZON-HLTH-2023- CARE-04, Programme: HORIZON. DG/Agency: HADEA. PICKED Project ID 101168626 HORIZON-MSCA-2023-DN-01-01 MSCA Doctoral Networks 2023. This paper is part of a Supplement that was financially supported by the ERA. The topic of this paper was also presented at the 61st ERA Congress, Stockholm & Virtual, May 23-26, 2024.

Análisis de autorías institucional

Compartir

GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity

Publicado en:Clinical Kidney Journal. 17 (Suppl 2): 19-35 - 2024-11-22 17(Suppl 2), DOI: 10.1093/ckj/sfae296

Autores: Abasheva, Daria; Ortiz, Alberto; Fernandez-Fernandez, Beatriz

Afiliaciones

Resumen

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular-kidney-metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) >= 30 kg/m(2)] or with overweight (BMI >= 27 kg/m(2)) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others. Additionally, liraglutide and semaglutide are approved to reduce CVD risk in patients with CVD and T2DM. Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD (FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity (SELECT trial). Thus, nephrologists should consider prescribing GLP-1 RAs to improve metabolic control, reduce CVD risk or improve kidney outcomes in three scenarios: patients with overweight and a related comorbid condition such as hypertension, dyslipidaemia or CVD, patients with obesity and patients with T2DM. This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health.

Palabras clave